X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://endpts.com/cardiff-teases-plk1-inhibitor-efficacy-in-colorectal-cancer-ahead-of-first-line-readout/
https://www.prnewswire.com/news-releases/cardiff-oncology-announces-plans-for-a-randomized-trial-in-metastatic-colorectal-cancer-mcrc-durability-of-responses-in-ongoing-phase-1b2-trial-in-mcrc-and-additional-business-updates-301622266.html
https://www.prnewswire.com/news-releases/cardiff-oncology-announces-new-preclinical-and-clinical-data-from-program-in-kras-mutated-metastatic-colorectal-cancer-mcrc-at-the-esmo-congress-2022-301621536.html
https://www.prnewswire.com/news-releases/cardiff-oncology-announces-data-showing-the-combination-of-parp-inhibition-with-onvansertib-overcomes-parp-inhibitor-resistance-in-brca1-mutant-and-wildtype-patient-derived-xenograft-ovarian-cancer-models-301520694.html
https://cardiffoncology.investorroom.com/2022-01-18-Cardiff-Oncology-Announces-New-Data-from-Lead-Clinical-Program-in-KRAS-mutated-Metastatic-Colorectal-Cancer-Showing-Robust-Objective-Response-Rate-and-Progression-Free-Survival
https://www.precisiononcologynews.com/business-news/pfizer-makes-15m-equity-investment-cardiff-oncology#.YZdW-WBBzIU
https://www.biospace.com/article/releases/cardiff-oncology-announces-first-patient-dosed-in-a-phase-2-trial-of-onvansertib-in-combination-with-irinotecan-and-5-fu-in-pancreatic-cancer/
https://www.prnewswire.com/news-releases/cardiff-oncology-presents-data-at-ash-demonstrating-the-safety-and-anti-leukemic-activity-of-onvansertib-in-patients-with-relapsedrefractory-aml-301186834.html
https://www.prnewswire.com/news-releases/cardiff-oncology-announces-expanded-access-program-for-onvansertib-in-kras-mutated-metastatic-colorectal-cancer-as-follow-on-to-fast-track-designation-301072576.html
https://www.prnewswire.com/news-releases/cardiff-oncology-enters-agreement-with-poc-capital-to-fund-phase-2-clinical-trial-of-onvansertib-in-kras-mutated-metastatic-colorectal-cancer-mcrc-301058326.html
https://www.prnewswire.com/news-releases/onvansertib-trial-in-kras-mutated-colorectal-cancer-demonstrates-consistent-tumor-regression-across-kras-mutation-subtypes-and-durable-response-301048164.html
Market Place
Share 
